📣 VC round data is live. Check it out!
- Public Comps
- Sinocare
Sinocare Valuation Multiples
Discover Sinocare's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like SonoScape, Tandem Diabetes Care, Daan Gene, Enovis and more.
Sinocare Overview
About Sinocare
Sinocare Inc operates in the healthcare industry. It is engaged in the development, manufacturing, and marketing of diagnosis testing products for people with chronic diseases and healthcare professionals. Its product range covers household blood glucose meter, medical blood glucose meter, urinary microalbumin test strip and blood lipid uric acid products. In addition, the company also provides diabetes management information systems.
Founded
2002
HQ

Employees
N/A
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialSinocare Financials
Sinocare reported last 12-month revenue of $712M and EBITDA of $74M.
In the same LTM period, Sinocare generated $357M in gross profit, $74M in EBITDA, and $31M in net income.
Revenue (LTM)
Sinocare P&L
In the most recent fiscal year, Sinocare reported revenue of $689M and EBITDA of $57M.
Sinocare is profitable as of last fiscal year, with gross margin of 49%, EBITDA margin of 8%, and net margin of 2%.
Financial data powered by Morningstar, Inc.
Sinocare Stock Performance
Sinocare has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Sinocare's stock price is $2.29.
Sinocare share price decreased by 0.2% in the last 30 days, and by 30.1% in the last year.
Sinocare has an EPS (earnings per share) of $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -1.3% | -0.2% | -1.5% | -30.1% | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSinocare Valuation Multiples
Sinocare trades at 1.8x EV/Revenue multiple, and 17.2x EV/EBITDA.
EV / Revenue (LTM)
Sinocare Financial Valuation Multiples
As of June 3, 2026, Sinocare has market cap of $1B and EV of $1B.
Sinocare has a P/E ratio of 40.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sinocare Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Sinocare Margins & Growth Rates
Sinocare grew revenue by 9% and EBITDA by 71% in the last fiscal year.
In the most recent fiscal year, Sinocare reported gross margin of 49%, EBITDA margin of 8%, and net margin of 2%.
Sinocare Margins
Sinocare Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Sinocare Operational KPIs
Sinocare's Rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sinocare's Rule of X is 36% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Sinocare Competitors
Sinocare competitors include SonoScape, Tandem Diabetes Care, Daan Gene, Enovis, AtriCure, AdaptHealth, NeoGenomics, Wandong Medical, VCANBIO and Integra Lifesciences.
Most Sinocare public comparables operate across Medical Devices, Medical Imaging & Diagnostics, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.3x | 3.1x | 27.8x | 24.6x | |||
| 1.4x | 1.4x | (31.2x) | (430.9x) | |||
| 10.4x | - | (17.3x) | - | |||
| 1.2x | 1.2x | 6.6x | 6.4x | |||
| 2.3x | 2.2x | 20.0x | 17.7x | |||
| 1.0x | 1.0x | 5.3x | 5.0x | |||
| 2.2x | 2.1x | 36.4x | 32.4x | |||
| 4.5x | 4.3x | (24.0x) | - | |||
This data is available for Pro users. Sign up to see all Sinocare competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Sinocare
Sinocare has acquired 2 companies to date.
Last acquisition by Sinocare was on May 3rd 2016. Sinocare acquired Polymer Technology Systems, Inc for $200M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Sinocare
| Description | Polymer Technology Systems, Inc. is an Indiana-based developer of point-of-care diagnostics under PTS Diagnostics, producing rapid tests for cholesterol, lipids, glucose, and kidney function. FDA-clebotomy cleared products like CardioChek and A1CNow serve clinics and pharmacies, with distribution in 50 countries since 1989. | Trividia Health is a Fort Lauderdale-headquartered developer and manufacturer of diabetes management products including blood glucose meters and test strips. Formerly Nipro Diagnostics, the company operates production facilities in Florida, New Hampshire, and Taiwan to supply global markets with monitoring technologies. |
| HQ Country | ||
| HQ City | Indianapolis, IN | Fort Lauderdale, FL |
| Deal Date | 3 May 2016 | 27 Oct 2015 |
| Valuation | $200M | $273M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Sinocare acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by Sinocare
Sinocare has invested in 1 company to date.
Latest investment by Sinocare was on February 18th 2021. Sinocare invested in SPH Health Commerce in their $160M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by Sinocare
| Description | - |
| HQ Country | |
| HQ City | - |
| Deal Date | 18 Feb 2021 |
| Round | Series B |
| Raised | $160M |
| Investors | Ample Harvest Finance; Huadong Industrial; JIC Investment; New Alliance Capital; Shanghai Biomedical Industrial Equity Investment Fund; Shanghai Minority Asset Management; Sinocare |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Sinocare investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sinocare
| When was Sinocare founded? | Sinocare was founded in 2002. |
| Where is Sinocare headquartered? | Sinocare is headquartered in China. |
| Is Sinocare publicly listed? | Yes, Sinocare is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Sinocare? | Sinocare trades under 300298 ticker. |
| When did Sinocare go public? | Sinocare went public in 2012. |
| Who are competitors of Sinocare? | Sinocare main competitors include SonoScape, Tandem Diabetes Care, Daan Gene, Enovis, AtriCure, AdaptHealth, NeoGenomics, Wandong Medical, VCANBIO, Integra Lifesciences. |
| What is the current market cap of Sinocare? | Sinocare's current market cap is $1B. |
| What is the current revenue of Sinocare? | Sinocare's last 12 months revenue is $712M. |
| What is the current revenue growth of Sinocare? | Sinocare revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Sinocare? | Current revenue multiple of Sinocare is 1.8x. |
| What is the current EBITDA of Sinocare? | Sinocare's last 12 months EBITDA is $74M. |
| What is Sinocare's EBITDA margin? | Sinocare's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Sinocare? | Current EBITDA multiple of Sinocare is 17.2x. |
| How many companies Sinocare has acquired to date? | As of June 2026, Sinocare has acquired 2 companies. |
| What was the largest acquisition by Sinocare? | $273M acquisition of Trividia Health on 27th October 2015 was the largest M&A Sinocare has done to date. |
| What companies Sinocare acquired? | Sinocare acquired Trividia Health and Polymer Technology Systems, Inc. |
| In how many companies Sinocare has invested to date? | As of June 2026, Sinocare has invested in 1 company. |
| What was the last Sinocare investment? | On 18th February 2021 Sinocare invested in SPH Health Commerce, participating in a $160M Series B round, alongside Ample Harvest Finance, Huadong Industrial, JIC Investment, New Alliance Capital, Shanghai Biomedical Industrial Equity Investment Fund, and Shanghai Minority Asset Management. |
| In what companies Sinocare invested in? | Sinocare invested in SPH Health Commerce. |
See public comps similar to Sinocare
Lists including Sinocare
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

